What is BRVE's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 1.97B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for BRVE?

P/E (TTM) is n/a and 52-week range is $17.86 to $32.00 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s BRVE figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for BRVE?

The company profile lists net income (TTM) near -$112M, EPS (TTM) near -$1.25 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Braveheart Bio, Inc. based, and what identifiers does Chartloom list?

The company context section lists headquarters in San Francisco, California, US, 90M shares outstanding, ISIN US10567X1019 when available from company profile and filing metadata.

Braveheart Bio, Inc.

$BRVE

Health Care · Pharmaceuticals

Run Scenarios

Browse other companiesFree AI scores and summaries for more stocks

Braveheart Bio, Inc.

$BRVE

Health Care · Pharmaceuticals

Run Scenarios

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. The company is headquartered in San Francisco, California and currently employs 30 full-time employees. The firm is focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Its lead product candidate, BHB 1893, is an oral small-molecule cardiac myosin inhibitor (CMI), that it is developing for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Its pipeline is focused on advancing BHB-1893 across multiple cardiovascular indications with significant unmet need. HCM is a chronic, progressive disease characterized by abnormal thickening and impaired relaxation of the heart.

Employees

30

Website

www.braveheart.bio

IPO

2026-08-06

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US10567X1019

Headquarters

San Francisco, California, US

Shares outstanding

90M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

6.52%

Browse other companiesFree AI scores and summaries for more stocks

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. The company is headquartered in San Francisco, California and currently employs 30 full-time employees. The firm is focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Its lead product candidate, BHB 1893, is an oral small-molecule cardiac myosin inhibitor (CMI), that it is developing for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Its pipeline is focused on advancing BHB-1893 across multiple cardiovascular indications with significant unmet need. HCM is a chronic, progressive disease characterized by abnormal thickening and impaired relaxation of the heart.

Employees

30

Website

www.braveheart.bio

IPO

2026-08-06

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)